AR092971A1 - Inhibidores de agrecanasa - Google Patents

Inhibidores de agrecanasa

Info

Publication number
AR092971A1
AR092971A1 ARP130103679A ARP130103679A AR092971A1 AR 092971 A1 AR092971 A1 AR 092971A1 AR P130103679 A ARP130103679 A AR P130103679A AR P130103679 A ARP130103679 A AR P130103679A AR 092971 A1 AR092971 A1 AR 092971A1
Authority
AR
Argentina
Prior art keywords
agrecanasa
inhibitors
cyclopropyl
intermediates
propyl
Prior art date
Application number
ARP130103679A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR092971A1 publication Critical patent/AR092971A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Abstract

La presente se refiere a compuestos que tienen la fórmula (1) en donde R¹ se selecciona a partir de metilo, etilo, propilo, ciclopropilo, y dimetilo, o una sal de los mismos farmacéuticamente aceptable, junto con métodos e intermediarios para su preparación, y usos de los mismos.
ARP130103679A 2012-10-26 2013-10-10 Inhibidores de agrecanasa AR092971A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261718965P 2012-10-26 2012-10-26

Publications (1)

Publication Number Publication Date
AR092971A1 true AR092971A1 (es) 2015-05-06

Family

ID=49515523

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103679A AR092971A1 (es) 2012-10-26 2013-10-10 Inhibidores de agrecanasa

Country Status (20)

Country Link
US (1) US9206139B2 (es)
EP (1) EP2912021B1 (es)
JP (1) JP6251279B2 (es)
KR (1) KR101689983B1 (es)
CN (1) CN104755464B (es)
AR (1) AR092971A1 (es)
AU (1) AU2013334989B2 (es)
BR (1) BR112015009032B1 (es)
CA (1) CA2886526C (es)
DK (1) DK2912021T3 (es)
EA (1) EA026037B1 (es)
ES (1) ES2645970T3 (es)
HK (1) HK1211927A1 (es)
HU (1) HUE034616T2 (es)
MX (1) MX364207B (es)
NZ (1) NZ706772A (es)
PL (1) PL2912021T3 (es)
PT (1) PT2912021T (es)
TW (1) TWI620738B (es)
WO (1) WO2014066151A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061377A2 (en) 2014-10-16 2016-04-21 Monsanto Technology Llc Lepidopteran-active cry1da1 amino acid sequence variant proteins
JO3501B1 (ar) * 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)
GB201610056D0 (en) * 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
GB201610055D0 (en) * 2016-06-09 2016-07-27 Galapagos Nv And Laboratoires Servier Les Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis
WO2021011723A1 (en) * 2019-07-18 2021-01-21 Avidence Therapeutics, Inc. Anti-osteoarthritis hydantoin compounds and related compositions and methods
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
WO2021214637A1 (en) * 2020-04-20 2021-10-28 St. Jude Children's Research Hospital Composition and methods for treating respiratory diseases
CN115720578A (zh) * 2020-07-09 2023-02-28 深圳信立泰药业股份有限公司 并三环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1397137B1 (en) * 2001-05-25 2009-10-14 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
MX2007016270A (es) * 2005-06-27 2008-03-05 Amgen Inc Compuestos aril nitrilo anti-inflamatorios.
KR20080031379A (ko) * 2005-07-11 2008-04-08 와이어쓰 글루타메이트 아그레카나제 저해제
PE20071240A1 (es) * 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
PL2912021T3 (pl) 2018-01-31
KR101689983B1 (ko) 2016-12-26
US20150218107A1 (en) 2015-08-06
CA2886526A1 (en) 2014-05-01
AU2013334989A1 (en) 2015-04-23
CN104755464B (zh) 2017-03-29
PT2912021T (pt) 2017-11-14
BR112015009032A2 (pt) 2017-07-04
BR112015009032B1 (pt) 2022-06-28
US9206139B2 (en) 2015-12-08
WO2014066151A1 (en) 2014-05-01
MX2015005297A (es) 2015-07-17
CN104755464A (zh) 2015-07-01
JP6251279B2 (ja) 2017-12-20
EA201590621A1 (ru) 2015-07-30
KR20150058480A (ko) 2015-05-28
MX364207B (es) 2019-04-16
EP2912021B1 (en) 2017-08-16
JP2015535248A (ja) 2015-12-10
ES2645970T3 (es) 2017-12-11
EA026037B1 (ru) 2017-02-28
AU2013334989B2 (en) 2016-02-18
TW201427955A (zh) 2014-07-16
EP2912021A1 (en) 2015-09-02
DK2912021T3 (en) 2017-10-02
HUE034616T2 (en) 2018-02-28
NZ706772A (en) 2018-05-25
CA2886526C (en) 2018-03-27
HK1211927A1 (en) 2016-06-03
TWI620738B (zh) 2018-04-11

Similar Documents

Publication Publication Date Title
AR092971A1 (es) Inhibidores de agrecanasa
CU20180059A7 (es) Compuestos inhibidores de la quinasa de unión a tank
CR20160098A (es) Polimorfo de los inhibidores de la syk
DK2812431T3 (da) Peptidblandinger til generering af multivirale ctl'er med bred specificitet
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CR20140134A (es) Composiciones farmacéuticas
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
BR112015022077A2 (pt) composto de pirazol-amida e usos medicinais do mesmo
CL2013002123A1 (es) Composicion herbicida que comprende topramezona y pinoxaden; uso de dicha composicion para controlar vegetación indeseable; formulación indeseable.
CR20150663A (es) Derivados de diazacarbazol como ligandos de tau para pet
DK2755481T3 (da) Anvendelse af alginatoligomerer til at forøge virkningerne af svampemidler
CO6960548A2 (es) Polimorfos de arry-380, un inhibidor selectivo de herb2 y composiciones farmacéuticas que los contienen
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
BR112012018086A2 (pt) método para gerar vapor d'água
BR112012031861A2 (pt) uso de 5a-androstano (alquil)-3b, 5, 6b-triol
CO7010828A2 (es) Preparación farmacéutica que comprende ߖciclodextrina sustituida
FR2973378B1 (fr) Derives d'acide hydroxybisphosphonique bifonctionnels
CR20150160A (es) Derivados de macrólidos, su preparación y su uso terapéutico
CL2014002033A1 (es) Compuestos derivados de dihidrofurano-azetidina y sus sales; composicion farmaceutica o veterinaria que los comprende; y su uso para tratar una infeccion o infestacion parasitaria.
AR092627A1 (es) Derivados glucopiranosidos de urea
BR302012005033S1 (pt) " configuração aplicada em um suporte para toalha "
ITMI20110184A1 (it) Composti fotosensibilizzanti "metal free"

Legal Events

Date Code Title Description
FG Grant, registration